U.S. market Closed. Opens in 5 hours 49 minutes

TAK | Takeda Pharmaceutical Company Limited Stock Overview

(Stock Exchange: NYSE)
Day's Range 13.95 - 14.11
52 Week Range 12.58 - 15.08
Beta 0.24
Implied Volatility 35.81%
IV Rank 62.26%
Day's Volume 1,482,636
Average Volume 1,823,500
Shares Outstanding 3,170,365,970
Market Cap 44,543,641,879
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 2010-01-05
Valuation
Profitability
Growth
Health
P/E Ratio 45.32
Forward P/E Ratio 6.44
EPS 0.31
1YR Price Target 16.40
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate 2021-09-29
Dividend PayDate 2021-12-13
Employees 49,281
Country Japan
Website TAK
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.
TAK's peers: BHC, VTRS, ELAN, ZTS, EBS, PBH, AMPH, DCPH, PCRX, COLL, SIGA, INVVY, ESPR, CTLT, EVO, EGRX, NBIX, PAHC, TEVA, HLN
*Chart delayed
Analyzing fundamentals for TAK we got that it has average fundamentals where Valuation is considered to be undervalued, Profitability is unacceptably poor, Growth is exceptionally good and Health is very weak. For more detailed analysis please see TAK Fundamentals page.

Watching at TAK technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on TAK Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙